Ua paʻi ʻo Kauka Yu Baofa a me kahi hui mai ʻAmelika Hui Pū ʻIa i kahi ʻatikala ma ka Journal of Gastroenterology Research and Practice 

ʻO ke kumu o kēia noiʻi ʻana ʻo ia ka loiloi i ke koʻikoʻi o nā autoantibodies kūʻē iā GNA11, MSLN, GNAS, CEBPA, MDM2, p16, Sui1, Calnuc, PTEN i ka maʻi pancreatic (PC). Ua hoʻokomo ʻia he 33 serum samples mai nā maʻi PC a me 45 serum samples mai nā mana maʻamau (NC), a ua ʻike ʻia nā ʻano autoantibodies 9 me ka hoʻohana ʻana i ka enzyme-linked immunosorbent assay (ELISA). E loiloi i ka hoʻohana ʻana i nā ʻāpana he nui ma ke ʻano hoʻokahi a i hui pū ʻia. Koe no ka anti GNAS a me ka anti calNUC, ʻoi aku ka kiʻekiʻe o nā kiʻekiʻe o nā autoantibodies ʻē aʻe ma mua o nā mea i loko o ka pūʻulu mana maʻamau. Ke hoʻohālikelikeʻia me ka pūʻulu mana maʻamau (4.9%), ua hoʻonui nuiʻia nā alapine o nā autoantibodiesʻehā, MSLN, p16, PTEN, a me Sui1, ma 75.8%, 66.7%, 30.3%, a me 27.3%. ʻO ka hiki o kēia mau autoantibodies ke hoʻokaʻawale i ka wahi ma lalo o ka ROC curve (AUC) mai 0.666 a 0.884, me ka anti-p16 (AUC o 0.884) a me ka anti MSLN (AUC o 0.857) e hōʻike ana i ka hana diagnostic ikaika loa. Hiki i ka hui pū ʻana o anti-MSLN a me anti-p16 ke hoʻomaikaʻi i ka ʻike o ka maʻi.